Survival benefit of neoadjuvant chemotherapy and surgery versus surgery first for resectable colorectal liver metastases: a cohort study.

MLA

Behrenbruch, Corina, et al. “Survival Benefit of Neoadjuvant Chemotherapy and Surgery versus Surgery First for Resectable Colorectal Liver Metastases: A Cohort Study.” ANZ Journal of Surgery, vol. 91, no. 6, June 2021, pp. 1196–202. EBSCOhost, https://doi.org/10.1111/ans.16613.

APA

Behrenbruch, C., Prabhakaran, S., Udayasiri, D., Hollande, F., Michael, M., Hayes, I., Heriot, A., Knowles, B., & Thomson, B. (2021). Survival benefit of neoadjuvant chemotherapy and surgery versus surgery first for resectable colorectal liver metastases: a cohort study. ANZ Journal of Surgery, 91(6), 1196–1202. https://doi.org/10.1111/ans.16613

Chicago

Behrenbruch, Corina, Sowmya Prabhakaran, Dilshan Udayasiri, Frédéric Hollande, Michael Michael, Ian Hayes, Alexander Heriot, Brett Knowles, and Benjamin Thomson. 2021. “Survival Benefit of Neoadjuvant Chemotherapy and Surgery versus Surgery First for Resectable Colorectal Liver Metastases: A Cohort Study.” ANZ Journal of Surgery 91 (6): 1196–1202. doi:10.1111/ans.16613.